|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-8-6
|
|
pubmed:abstractText |
Targeting the epidermal growth factor receptor and angiogenesis have proven useful strategies against metastatic colorectal cancer. The benefit of combining inhibitors of both pathways is unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/erlotinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BattaGG,
pubmed-author:BhargavaPP,
pubmed-author:BlaszkowskyLL,
pubmed-author:EarleC CCC,
pubmed-author:EnzingerPP,
pubmed-author:FuchsC SCS,
pubmed-author:LawrenceCC,
pubmed-author:MayerR JRJ,
pubmed-author:MeyerhardtJ AJA,
pubmed-author:RyanD PDP,
pubmed-author:StuartKK,
pubmed-author:ZhuA XAX
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1185-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17483115-Adenocarcinoma,
pubmed-meshheading:17483115-Adult,
pubmed-meshheading:17483115-Aged,
pubmed-meshheading:17483115-Aged, 80 and over,
pubmed-meshheading:17483115-Antibodies, Monoclonal,
pubmed-meshheading:17483115-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17483115-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17483115-Colorectal Neoplasms,
pubmed-meshheading:17483115-Female,
pubmed-meshheading:17483115-Fluorouracil,
pubmed-meshheading:17483115-Humans,
pubmed-meshheading:17483115-Kaplan-Meier Estimate,
pubmed-meshheading:17483115-Leucovorin,
pubmed-meshheading:17483115-Male,
pubmed-meshheading:17483115-Middle Aged,
pubmed-meshheading:17483115-Organoplatinum Compounds,
pubmed-meshheading:17483115-Quinazolines
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jmeyerhardt@partners.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
